Generic Name and Formulations:
Lifitegrast 5%; oph soln.
Shire US, Inc.
Indications for XIIDRA:
Signs and symptoms of dry eye disease.
Instill 1 drop twice daily (~12hrs apart) in each eye.
<17yrs: not established.
Remove contact lens prior to use; may reinsert 15mins after administration. Pregnancy. Nursing mothers.
Lymphocyte function-associated antigen-1 (LFA-1) antagonist.
Instillation site irritation, dysgeusia, decreased visual acuity; hypersensitivity.
Single-use containers (0.2mL)—60
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally